Sign in

NCT07359482RecruitingPhase 3

sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT

Source: ClinicalTrials.gov · Last updated 9 Jun 2026

Brief summary (registry, in English)

Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed. A promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks. The investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
160 (estimated)
First submitted
14 Jan 2026
Start date
4 Jun 2026
Primary completion date
31 Dec 2027
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT number
NCT07359482

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 160
  • From 4 Jun 2026 to the primary completion date, 31 Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of medication with interaction with fluvoxamine that cannot be discontinued
  • known current alcohol or drug use problems.
  • having metal implants (optional MRI substudy)

Other illness

  • Hospitalized in the acute phase of Covid-19
  • Psychiatric/somatic disorders that could explain the severity of fatigue
  • Neurodegenerative disorders (i.e. M Parkinson, Multiple sclerosis, M Alzheimer)
  • Starting or started with other medication intended to reduce post-covid symptoms during the last 2 months
  • epilepsy, porphyria, history of severe liver impairment
  • known allergies to fluvoxamine or placebo/excipients
  • Bleeding disorders and past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders
  • Neurotrauma/ large stroke or brain abnormalities interfering with image analyses (optional MRI substudy)

Lab values

  • Pregnancy (a positive urine or serum pregnancy test) or unwilling to use standard contraception
  • Brugada- or Long QT interval syndrome

Other

  • Suicidality (current or recent) (according to WHO suicide screener)
  • claustrophobia (optional MRI substudy)
  • inability to lay still for 45 minutes (optional MRI substudy)
  • Inability to come to the Amsterdam UMC (optional MRI substudy).

Who the study is looking for

  • Adults aged 18 to 70 years
  • Severely fatigued (CIS fatigue score ≥ 35) at screening
  • Fatigue started/increased significantly after Covid-19 (self-declared)
  • Fatigue symptoms must be present for at least 3 months following the acute infection.
  • Self-reported confirmation of having a SARS-CoV-2 infection by: Positive SARS-CoV-2 nucleic acid amplification test (NAAT), such as PCR; Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests; COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical test or assessments. The above information will not be verified in medical records.
  • Command of Dutch or English language to complete questionnaires
  • Able to participate in video calling.
  • Willing and able to provide informed consent
  • Allowing the trial team to exchange medical information that is relevant for the participants' safety and trial assessments with their GP and pharmacy.

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Amsterdam UMC
Coordinator of this site? Confirm its status		Amsterdam-ZuidoostNetherlandsRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.